FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1897988280> ?p ?o ?g. }

• W1897988280 endingPage "50" @default.
• W1897988280 startingPage "41" @default.
• W1897988280 abstract "The nonnucleoside reverse transcriptase inhibitor etravirine, approved for use in treatment-experienced, HIV-1-infected patients, is a substrate and inducer of cytochrome P450 (CYP) 3A4 and a substrate and inhibitor of CYP2C9/CYP2C19. Pharmacokinetic interactions and safety of etravirine 200 mg twice daily coadministered with fluconazole 200 mg daily or voriconazole 200 mg twice daily, both inhibitors of CYP3A4, CYP2C9, and CYP2C19, were evaluated in an open-label, randomized, 3-period crossover trial in 18 HIV-negative volunteers. Based on least squares means (LSM) ratios, coadministration of etravirine with fluconazole or voriconazole resulted in higher etravirine exposures (area under plasma concentration-time curve from 0-12 hours [AUC12 h] 1.86- and 1.36-fold, respectively). Fluconazole pharmacokinetics were unchanged with etravirine coadministration (AUC12 h LSM ratio: 0.94), and voriconazole plasma concentrations were slightly raised (AUC12 h LSM ratio: 1.14). All treatments and combinations were well tolerated, with no grade 3 or 4 adverse events observed during treatment. There was 1 adverse event–related trial withdrawal during treatment with fluconazole alone (leukocyturia). The most frequent adverse events were headache and blurred vision (11 and 8 volunteers, respectively), with blurred vision occurring exclusively during voriconazole-alone treatment. Pharmacokinetic interactions between etravirine and fluconazole or voriconazole are not expected to be clinically relevant; no dose adjustments are required during coadministration." @default.
• W1897988280 created "2016-06-24" @default.
• W1897988280 creator A5007418920 @default.
• W1897988280 creator A5009511308 @default.
• W1897988280 creator A5011950226 @default.
• W1897988280 creator A5030426323 @default.
• W1897988280 creator A5045102886 @default.
• W1897988280 creator A5046228013 @default.
• W1897988280 creator A5086420860 @default.
• W1897988280 creator A5088020835 @default.
• W1897988280 date "2013-01-01" @default.
• W1897988280 modified "2023-09-23" @default.
• W1897988280 title "Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers" @default.
• W1897988280 cites W16565033 @default.
• W1897988280 cites W179970603 @default.
• W1897988280 cites W1852367001 @default.
• W1897988280 cites W1890388819 @default.
• W1897988280 cites W1970975200 @default.
• W1897988280 cites W1982177139 @default.
• W1897988280 cites W1984117544 @default.
• W1897988280 cites W1999580368 @default.
• W1897988280 cites W2003077790 @default.
• W1897988280 cites W2015677019 @default.
• W1897988280 cites W2028933711 @default.
• W1897988280 cites W2045730529 @default.
• W1897988280 cites W2046246036 @default.
• W1897988280 cites W2057772850 @default.
• W1897988280 cites W2065343663 @default.
• W1897988280 cites W2074411784 @default.
• W1897988280 cites W2115179464 @default.
• W1897988280 cites W2118370392 @default.
• W1897988280 cites W2121179908 @default.
• W1897988280 cites W2156933277 @default.
• W1897988280 cites W2172130850 @default.
• W1897988280 cites W2316050656 @default.
• W1897988280 cites W4241267536 @default.
• W1897988280 doi "https://doi.org/10.1177/0091270011433329" @default.
• W1897988280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23400742" @default.
• W1897988280 hasPublicationYear "2013" @default.
• W1897988280 type Work @default.
• W1897988280 sameAs 1897988280 @default.
• W1897988280 citedByCount "5" @default.
• W1897988280 countsByYear W18979882802013 @default.
• W1897988280 countsByYear W18979882802016 @default.
• W1897988280 countsByYear W18979882802017 @default.
• W1897988280 countsByYear W18979882802019 @default.
• W1897988280 countsByYear W18979882802023 @default.
• W1897988280 crossrefType "journal-article" @default.
• W1897988280 hasAuthorship W1897988280A5007418920 @default.
• W1897988280 hasAuthorship W1897988280A5009511308 @default.
• W1897988280 hasAuthorship W1897988280A5011950226 @default.
• W1897988280 hasAuthorship W1897988280A5030426323 @default.
• W1897988280 hasAuthorship W1897988280A5045102886 @default.
• W1897988280 hasAuthorship W1897988280A5046228013 @default.
• W1897988280 hasAuthorship W1897988280A5086420860 @default.
• W1897988280 hasAuthorship W1897988280A5088020835 @default.
• W1897988280 hasConcept C112705442 @default.
• W1897988280 hasConcept C126322002 @default.
• W1897988280 hasConcept C142462285 @default.
• W1897988280 hasConcept C142724271 @default.
• W1897988280 hasConcept C16005928 @default.
• W1897988280 hasConcept C197934379 @default.
• W1897988280 hasConcept C203014093 @default.
• W1897988280 hasConcept C204787440 @default.
• W1897988280 hasConcept C27081682 @default.
• W1897988280 hasConcept C2777351918 @default.
• W1897988280 hasConcept C2779548794 @default.
• W1897988280 hasConcept C2780345285 @default.
• W1897988280 hasConcept C2780651595 @default.
• W1897988280 hasConcept C2780690907 @default.
• W1897988280 hasConcept C2993143319 @default.
• W1897988280 hasConcept C3013748606 @default.
• W1897988280 hasConcept C71924100 @default.
• W1897988280 hasConcept C87813604 @default.
• W1897988280 hasConcept C97320921 @default.
• W1897988280 hasConcept C98274493 @default.
• W1897988280 hasConceptScore W1897988280C112705442 @default.
• W1897988280 hasConceptScore W1897988280C126322002 @default.
• W1897988280 hasConceptScore W1897988280C142462285 @default.
• W1897988280 hasConceptScore W1897988280C142724271 @default.
• W1897988280 hasConceptScore W1897988280C16005928 @default.
• W1897988280 hasConceptScore W1897988280C197934379 @default.
• W1897988280 hasConceptScore W1897988280C203014093 @default.
• W1897988280 hasConceptScore W1897988280C204787440 @default.
• W1897988280 hasConceptScore W1897988280C27081682 @default.
• W1897988280 hasConceptScore W1897988280C2777351918 @default.
• W1897988280 hasConceptScore W1897988280C2779548794 @default.
• W1897988280 hasConceptScore W1897988280C2780345285 @default.
• W1897988280 hasConceptScore W1897988280C2780651595 @default.
• W1897988280 hasConceptScore W1897988280C2780690907 @default.
• W1897988280 hasConceptScore W1897988280C2993143319 @default.
• W1897988280 hasConceptScore W1897988280C3013748606 @default.
• W1897988280 hasConceptScore W1897988280C71924100 @default.
• W1897988280 hasConceptScore W1897988280C87813604 @default.
• W1897988280 hasConceptScore W1897988280C97320921 @default.
• W1897988280 hasConceptScore W1897988280C98274493 @default.
• W1897988280 hasIssue "1" @default.
• W1897988280 hasLocation W18979882801 @default.

• next